Loading…
Challenge infection model for MERS-CoV based on naturally infected camels
Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging virus that infects humans and camels with no approved antiviral therapy or vaccine. Some vaccines are in development for camels as a one-health intervention where vaccinating camels is proposed to reduce human viral exposure. Thi...
Saved in:
Published in: | Virology journal 2020-06, Vol.17 (1), p.1-77, Article 77 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723 |
---|---|
cites | cdi_FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723 |
container_end_page | 77 |
container_issue | 1 |
container_start_page | 1 |
container_title | Virology journal |
container_volume | 17 |
creator | Alharbi, Naif Khalaf Ibrahim, Osman H Alhafufi, Ali Kasem, Samy Aldowerij, Ali Albrahim, Raed Abu-obaidah, Ali Alkarar, Ali Bayoumi, Faisal Altaib Almansour, Ali Mohammed Aldubaib, Musaad Al-Abdely, Hail M Balkhy, Hanan H Qasim, Ibrahim |
description | Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging virus that infects humans and camels with no approved antiviral therapy or vaccine. Some vaccines are in development for camels as a one-health intervention where vaccinating camels is proposed to reduce human viral exposure. This intervention will require an understanding of the prior exposure of camels to the virus and appropriate vaccine efficacy studies in camels. We conducted a cross sectional seroprevalence study in young dromedary camels to determine the rate of MERS-CoV seropositivity in young camels. Next, we utilised naturally infected camels as a natural challenge model that can be used by co-housing these camels with healthy naive camels in a ratio of 1 to 2. This model is aimed to support studies on natural virus transmission as well as evaluating drug and vaccine efficacy. We found that 90% of the screened camels have pre-existing antibodies for MERS-CoV. In addition, the challenge model resulted in MERS-CoV transmission within 48 h with infections that continued for 14 days post challenge. Our finding suggests that the majority of young dromedary camels in Saudi Arabia are seropositive and that naturally infected camels can serve as a challenge model to assess transmission, therapeutics, and vaccine efficacy. |
doi_str_mv | 10.1186/s12985-020-01347-5 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7d42c3225e5e45f3a54ec954440aebd4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A627416503</galeid><doaj_id>oai_doaj_org_article_7d42c3225e5e45f3a54ec954440aebd4</doaj_id><sourcerecordid>A627416503</sourcerecordid><originalsourceid>FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723</originalsourceid><addsrcrecordid>eNptkkFv1DAQhSMEoqXwBzhF4kIPKfZ4HCcXpGpVYKVWSC0gbpZjT9KskrjYCaL_Hm93BV2EfLA1882z_fSy7DVnZ5xX5bvIoa5kwYAVjAtUhXySHXOFokCA708fnY-yFzFuGBNQqvp5diRASqgEP87Wq1szDDR1lPdTS3bu_ZSP3tGQtz7kVxfXN8XKf8sbE8nlqTeZeQlp5H7Pp6o1Iw3xZfasNUOkV_v9JPv64eLL6lNx-fnjenV-WVipcC5IOCKpDNQgKmddg9QiyfQyoUTdqhLA8VZI7pQiZ8qmUrUB62zjHCsViJNsvdN13mz0XehHE-61N71-KPjQaRPm3g6klUOwAkCSJJStMBLJ1hIRmaHGYdJ6v9O6W5qRnKVpTn87ED3sTP2t7vxPrZLziGUSeLsXCP7HQnHWYx8tDYOZyC9RA_JkNDJkCX3zD7rxS5iSVVsKq1pIVf2lOpM-kCz26V67FdXnJSjkpWQiUWf_odJyNPbWT9T2qX4wcHowkJiZfs2dWWLU65vrQxZ2rA0-xkDtHz8409vg6V3wdAqefgieluI35LXG8w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2414893578</pqid></control><display><type>article</type><title>Challenge infection model for MERS-CoV based on naturally infected camels</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Alharbi, Naif Khalaf ; Ibrahim, Osman H ; Alhafufi, Ali ; Kasem, Samy ; Aldowerij, Ali ; Albrahim, Raed ; Abu-obaidah, Ali ; Alkarar, Ali ; Bayoumi, Faisal Altaib ; Almansour, Ali Mohammed ; Aldubaib, Musaad ; Al-Abdely, Hail M ; Balkhy, Hanan H ; Qasim, Ibrahim</creator><creatorcontrib>Alharbi, Naif Khalaf ; Ibrahim, Osman H ; Alhafufi, Ali ; Kasem, Samy ; Aldowerij, Ali ; Albrahim, Raed ; Abu-obaidah, Ali ; Alkarar, Ali ; Bayoumi, Faisal Altaib ; Almansour, Ali Mohammed ; Aldubaib, Musaad ; Al-Abdely, Hail M ; Balkhy, Hanan H ; Qasim, Ibrahim</creatorcontrib><description>Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging virus that infects humans and camels with no approved antiviral therapy or vaccine. Some vaccines are in development for camels as a one-health intervention where vaccinating camels is proposed to reduce human viral exposure. This intervention will require an understanding of the prior exposure of camels to the virus and appropriate vaccine efficacy studies in camels. We conducted a cross sectional seroprevalence study in young dromedary camels to determine the rate of MERS-CoV seropositivity in young camels. Next, we utilised naturally infected camels as a natural challenge model that can be used by co-housing these camels with healthy naive camels in a ratio of 1 to 2. This model is aimed to support studies on natural virus transmission as well as evaluating drug and vaccine efficacy. We found that 90% of the screened camels have pre-existing antibodies for MERS-CoV. In addition, the challenge model resulted in MERS-CoV transmission within 48 h with infections that continued for 14 days post challenge. Our finding suggests that the majority of young dromedary camels in Saudi Arabia are seropositive and that naturally infected camels can serve as a challenge model to assess transmission, therapeutics, and vaccine efficacy.</description><identifier>ISSN: 1743-422X</identifier><identifier>EISSN: 1743-422X</identifier><identifier>DOI: 10.1186/s12985-020-01347-5</identifier><identifier>PMID: 32552831</identifier><language>eng</language><publisher>London: BioMed Central Ltd</publisher><subject>Age ; Antibodies ; Antiviral agents ; Biohazards ; Camelidae ; Camelus dromedarius ; Challenge model ; Coronaviruses ; Disease control ; Disease transmission ; Dromedary camels ; Farms ; Health aspects ; Infections ; Medical research ; MERS-CoV ; Middle East respiratory syndrome ; Provinces ; Respiratory diseases ; Saudi Arabia ; Serology ; Seroprevalence ; Studies ; Vaccination ; Vaccine efficacy ; Vaccines ; Viral infections</subject><ispartof>Virology journal, 2020-06, Vol.17 (1), p.1-77, Article 77</ispartof><rights>COPYRIGHT 2020 BioMed Central Ltd.</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723</citedby><cites>FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723</cites><orcidid>0000-0002-6049-3383</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298446/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2414893578?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793</link.rule.ids></links><search><creatorcontrib>Alharbi, Naif Khalaf</creatorcontrib><creatorcontrib>Ibrahim, Osman H</creatorcontrib><creatorcontrib>Alhafufi, Ali</creatorcontrib><creatorcontrib>Kasem, Samy</creatorcontrib><creatorcontrib>Aldowerij, Ali</creatorcontrib><creatorcontrib>Albrahim, Raed</creatorcontrib><creatorcontrib>Abu-obaidah, Ali</creatorcontrib><creatorcontrib>Alkarar, Ali</creatorcontrib><creatorcontrib>Bayoumi, Faisal Altaib</creatorcontrib><creatorcontrib>Almansour, Ali Mohammed</creatorcontrib><creatorcontrib>Aldubaib, Musaad</creatorcontrib><creatorcontrib>Al-Abdely, Hail M</creatorcontrib><creatorcontrib>Balkhy, Hanan H</creatorcontrib><creatorcontrib>Qasim, Ibrahim</creatorcontrib><title>Challenge infection model for MERS-CoV based on naturally infected camels</title><title>Virology journal</title><description>Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging virus that infects humans and camels with no approved antiviral therapy or vaccine. Some vaccines are in development for camels as a one-health intervention where vaccinating camels is proposed to reduce human viral exposure. This intervention will require an understanding of the prior exposure of camels to the virus and appropriate vaccine efficacy studies in camels. We conducted a cross sectional seroprevalence study in young dromedary camels to determine the rate of MERS-CoV seropositivity in young camels. Next, we utilised naturally infected camels as a natural challenge model that can be used by co-housing these camels with healthy naive camels in a ratio of 1 to 2. This model is aimed to support studies on natural virus transmission as well as evaluating drug and vaccine efficacy. We found that 90% of the screened camels have pre-existing antibodies for MERS-CoV. In addition, the challenge model resulted in MERS-CoV transmission within 48 h with infections that continued for 14 days post challenge. Our finding suggests that the majority of young dromedary camels in Saudi Arabia are seropositive and that naturally infected camels can serve as a challenge model to assess transmission, therapeutics, and vaccine efficacy.</description><subject>Age</subject><subject>Antibodies</subject><subject>Antiviral agents</subject><subject>Biohazards</subject><subject>Camelidae</subject><subject>Camelus dromedarius</subject><subject>Challenge model</subject><subject>Coronaviruses</subject><subject>Disease control</subject><subject>Disease transmission</subject><subject>Dromedary camels</subject><subject>Farms</subject><subject>Health aspects</subject><subject>Infections</subject><subject>Medical research</subject><subject>MERS-CoV</subject><subject>Middle East respiratory syndrome</subject><subject>Provinces</subject><subject>Respiratory diseases</subject><subject>Saudi Arabia</subject><subject>Serology</subject><subject>Seroprevalence</subject><subject>Studies</subject><subject>Vaccination</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Viral infections</subject><issn>1743-422X</issn><issn>1743-422X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkkFv1DAQhSMEoqXwBzhF4kIPKfZ4HCcXpGpVYKVWSC0gbpZjT9KskrjYCaL_Hm93BV2EfLA1882z_fSy7DVnZ5xX5bvIoa5kwYAVjAtUhXySHXOFokCA708fnY-yFzFuGBNQqvp5diRASqgEP87Wq1szDDR1lPdTS3bu_ZSP3tGQtz7kVxfXN8XKf8sbE8nlqTeZeQlp5H7Pp6o1Iw3xZfasNUOkV_v9JPv64eLL6lNx-fnjenV-WVipcC5IOCKpDNQgKmddg9QiyfQyoUTdqhLA8VZI7pQiZ8qmUrUB62zjHCsViJNsvdN13mz0XehHE-61N71-KPjQaRPm3g6klUOwAkCSJJStMBLJ1hIRmaHGYdJ6v9O6W5qRnKVpTn87ED3sTP2t7vxPrZLziGUSeLsXCP7HQnHWYx8tDYOZyC9RA_JkNDJkCX3zD7rxS5iSVVsKq1pIVf2lOpM-kCz26V67FdXnJSjkpWQiUWf_odJyNPbWT9T2qX4wcHowkJiZfs2dWWLU65vrQxZ2rA0-xkDtHz8409vg6V3wdAqefgieluI35LXG8w</recordid><startdate>20200617</startdate><enddate>20200617</enddate><creator>Alharbi, Naif Khalaf</creator><creator>Ibrahim, Osman H</creator><creator>Alhafufi, Ali</creator><creator>Kasem, Samy</creator><creator>Aldowerij, Ali</creator><creator>Albrahim, Raed</creator><creator>Abu-obaidah, Ali</creator><creator>Alkarar, Ali</creator><creator>Bayoumi, Faisal Altaib</creator><creator>Almansour, Ali Mohammed</creator><creator>Aldubaib, Musaad</creator><creator>Al-Abdely, Hail M</creator><creator>Balkhy, Hanan H</creator><creator>Qasim, Ibrahim</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6049-3383</orcidid></search><sort><creationdate>20200617</creationdate><title>Challenge infection model for MERS-CoV based on naturally infected camels</title><author>Alharbi, Naif Khalaf ; Ibrahim, Osman H ; Alhafufi, Ali ; Kasem, Samy ; Aldowerij, Ali ; Albrahim, Raed ; Abu-obaidah, Ali ; Alkarar, Ali ; Bayoumi, Faisal Altaib ; Almansour, Ali Mohammed ; Aldubaib, Musaad ; Al-Abdely, Hail M ; Balkhy, Hanan H ; Qasim, Ibrahim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age</topic><topic>Antibodies</topic><topic>Antiviral agents</topic><topic>Biohazards</topic><topic>Camelidae</topic><topic>Camelus dromedarius</topic><topic>Challenge model</topic><topic>Coronaviruses</topic><topic>Disease control</topic><topic>Disease transmission</topic><topic>Dromedary camels</topic><topic>Farms</topic><topic>Health aspects</topic><topic>Infections</topic><topic>Medical research</topic><topic>MERS-CoV</topic><topic>Middle East respiratory syndrome</topic><topic>Provinces</topic><topic>Respiratory diseases</topic><topic>Saudi Arabia</topic><topic>Serology</topic><topic>Seroprevalence</topic><topic>Studies</topic><topic>Vaccination</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alharbi, Naif Khalaf</creatorcontrib><creatorcontrib>Ibrahim, Osman H</creatorcontrib><creatorcontrib>Alhafufi, Ali</creatorcontrib><creatorcontrib>Kasem, Samy</creatorcontrib><creatorcontrib>Aldowerij, Ali</creatorcontrib><creatorcontrib>Albrahim, Raed</creatorcontrib><creatorcontrib>Abu-obaidah, Ali</creatorcontrib><creatorcontrib>Alkarar, Ali</creatorcontrib><creatorcontrib>Bayoumi, Faisal Altaib</creatorcontrib><creatorcontrib>Almansour, Ali Mohammed</creatorcontrib><creatorcontrib>Aldubaib, Musaad</creatorcontrib><creatorcontrib>Al-Abdely, Hail M</creatorcontrib><creatorcontrib>Balkhy, Hanan H</creatorcontrib><creatorcontrib>Qasim, Ibrahim</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Virology journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alharbi, Naif Khalaf</au><au>Ibrahim, Osman H</au><au>Alhafufi, Ali</au><au>Kasem, Samy</au><au>Aldowerij, Ali</au><au>Albrahim, Raed</au><au>Abu-obaidah, Ali</au><au>Alkarar, Ali</au><au>Bayoumi, Faisal Altaib</au><au>Almansour, Ali Mohammed</au><au>Aldubaib, Musaad</au><au>Al-Abdely, Hail M</au><au>Balkhy, Hanan H</au><au>Qasim, Ibrahim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Challenge infection model for MERS-CoV based on naturally infected camels</atitle><jtitle>Virology journal</jtitle><date>2020-06-17</date><risdate>2020</risdate><volume>17</volume><issue>1</issue><spage>1</spage><epage>77</epage><pages>1-77</pages><artnum>77</artnum><issn>1743-422X</issn><eissn>1743-422X</eissn><abstract>Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging virus that infects humans and camels with no approved antiviral therapy or vaccine. Some vaccines are in development for camels as a one-health intervention where vaccinating camels is proposed to reduce human viral exposure. This intervention will require an understanding of the prior exposure of camels to the virus and appropriate vaccine efficacy studies in camels. We conducted a cross sectional seroprevalence study in young dromedary camels to determine the rate of MERS-CoV seropositivity in young camels. Next, we utilised naturally infected camels as a natural challenge model that can be used by co-housing these camels with healthy naive camels in a ratio of 1 to 2. This model is aimed to support studies on natural virus transmission as well as evaluating drug and vaccine efficacy. We found that 90% of the screened camels have pre-existing antibodies for MERS-CoV. In addition, the challenge model resulted in MERS-CoV transmission within 48 h with infections that continued for 14 days post challenge. Our finding suggests that the majority of young dromedary camels in Saudi Arabia are seropositive and that naturally infected camels can serve as a challenge model to assess transmission, therapeutics, and vaccine efficacy.</abstract><cop>London</cop><pub>BioMed Central Ltd</pub><pmid>32552831</pmid><doi>10.1186/s12985-020-01347-5</doi><orcidid>https://orcid.org/0000-0002-6049-3383</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1743-422X |
ispartof | Virology journal, 2020-06, Vol.17 (1), p.1-77, Article 77 |
issn | 1743-422X 1743-422X |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_7d42c3225e5e45f3a54ec954440aebd4 |
source | Publicly Available Content (ProQuest); PubMed Central; Coronavirus Research Database |
subjects | Age Antibodies Antiviral agents Biohazards Camelidae Camelus dromedarius Challenge model Coronaviruses Disease control Disease transmission Dromedary camels Farms Health aspects Infections Medical research MERS-CoV Middle East respiratory syndrome Provinces Respiratory diseases Saudi Arabia Serology Seroprevalence Studies Vaccination Vaccine efficacy Vaccines Viral infections |
title | Challenge infection model for MERS-CoV based on naturally infected camels |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A16%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Challenge%20infection%20model%20for%20MERS-CoV%20based%20on%20naturally%20infected%20camels&rft.jtitle=Virology%20journal&rft.au=Alharbi,%20Naif%20Khalaf&rft.date=2020-06-17&rft.volume=17&rft.issue=1&rft.spage=1&rft.epage=77&rft.pages=1-77&rft.artnum=77&rft.issn=1743-422X&rft.eissn=1743-422X&rft_id=info:doi/10.1186/s12985-020-01347-5&rft_dat=%3Cgale_doaj_%3EA627416503%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c574t-e3dee57a29238dcdb4ef4e53263739f7622d1f351d77eda6b879a2cdcbdd06723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2414893578&rft_id=info:pmid/32552831&rft_galeid=A627416503&rfr_iscdi=true |